Last reviewed · How we verify
Methadone-dexmedetomidine-ketamine combination
This combination uses methadone (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and ketamine (NMDA antagonist) together to produce anesthesia and analgesia.
This combination uses methadone (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and ketamine (NMDA antagonist) together to produce anesthesia and analgesia. Used for Anesthesia and analgesia (specific clinical applications not clearly defined in available literature).
At a glance
| Generic name | Methadone-dexmedetomidine-ketamine combination |
|---|---|
| Sponsor | University of Missouri-Columbia |
| Drug class | Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist) |
| Target | Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Methadone provides opioid-mediated analgesia and sedation. Dexmedetomidine enhances sedation and analgesia through alpha-2 adrenergic receptor activation while maintaining airway reflexes. Ketamine contributes dissociative anesthesia and analgesia via NMDA receptor antagonism. The combination is designed to provide balanced anesthesia with reduced individual drug requirements.
Approved indications
- Anesthesia and analgesia (specific clinical applications not clearly defined in available literature)
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Dissociative effects
Key clinical trials
- The MDK Study: Using a Combination of Methadone-dexmedetomidine-ketamine for Postoperative Pain Control in Patients Undergoing Complex Spine Surgeries. (PHASE4)
- Outcome of Multimodal Anesthesia Bern (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: